Richmond Laboratories signed an agreement with the Russian Direct Investment Fund in February to produce Sputnik V.
–
The Richmond Laboratories company announced this Friday that it had concluded the production of 550,000 new doses of component 1 of the Sputnik V vaccine, through its official Twitter account.
“Today, we finished the production of 550,000 new doses of component 1 of the #SputnikV vaccine,” he explained.
And he added that he continues “working with great effort and maximum energy with the commitment of local supply by making available the largest quantity of vaccines.”
Today, we finished the production of 550,000 new doses of component I of the vaccine #SputnikV.
We continue working with great effort and maximum energy with the commitment of local supply by making the largest quantity of vaccines available. pic.twitter.com/GAnGoH7uxXRichmond Lab (@richmond_lab) July 2, 2021
–
The president of Laboratorios Richmond, Marcelo Figueiras, highlighted days ago that the local production of Sputnik V against the coronavirus paves “the way towards sustainable health autonomy in the field of vaccines in Argentina”.
Regarding work, he indicated that it is a challenge that the company assumed and reaffirmed “the importance of work and team collaboration in science.”
In February of this year, Richmond Laboratories signed a memorandum of understanding with the Russian Direct Investment Fund (RDIF) to produce Sputnik V, a development in which the Hetero Indian laboratory participates, in charge of transferring the technology, with which the company Argentina has had a strategic alliance for more than 25 years.
– .
